Vir Biotechnology Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Marianne De Backer

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	1.3yrs
Board average tenure	6.9yrs

Recent management updates

Recent updates

CEO

Marianne De Backer (54 yo)

less than a year

Tenure

Dr. Marianne De Backer, MSc, Ph. D., MBA, served as Independent Director at Kronos Bio, Inc. from January 25, 2021 to June 2023. Dr. De Backer is Executive Vice President, Head of Global Business Developme...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Ann Hanly	Executive VP & Chief Technology Officer	2.8yrs	US$3.58m	0.011% MX$ 2.4m
Phillip Pang	Executive VP & Chief Medical Officer	5yrs	US$4.39m	0.039% MX$ 8.9m
Marianne De Backer	CEO & Director	less than a year	no data	no data
Klaus Frueh	Co-Founder & Scientific Advisor	7.9yrs	US$177.66k	no data
Lawrence Corey	Co-Founder & Scientific Advisor	7.9yrs	no data	no data
Louis Picker	Co-Founder & Scientific Advisor	no data	no data	no data
Sung Lee	Executive VP & CFO	less than a year	no data	no data
Jennifer Towne	Executive VP & Chief Scientific Officer	less than a year	no data	no data
Heather Armstrong	Vice President of Investor Relations	no data	no data	no data
Vanina Verneuil	Executive VP	1.3yrs	no data	no data
Cara Miller	Vice President of Corporate Communications	no data	no data	no data
Jenny Gumm	Executive VP & Chief Human Resources Officer	less than a year	no data	no data

1.3yrs

Average Tenure

53.5yo

Average Age

Experienced Management: VIR *'s management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Marianne De Backer	CEO & Director	less than a year	no data	no data
Klaus Frueh	Co-Founder & Scientific Advisor	4.9yrs	US$177.66k	no data
Lawrence Corey	Co-Founder & Scientific Advisor	no data	no data	no data
Louis Picker	Co-Founder & Scientific Advisor	no data	no data	no data
Robert Taylor Nelsen	Independent Director	7.7yrs	US$444.94k	0.44% MX$ 99.8m
Robert J. More	Independent Director	7.3yrs	US$464.94k	0.029% MX$ 6.5m
Vicki Sato	Independent Chairman	7yrs	US$488.21k	0.98% MX$ 219.7m
Phillip Sharp	Independent Director	6.9yrs	US$454.94k	0.18% MX$ 40.4m
George Scangos	Director	6.9yrs	US$7.48m	2.78% MX$ 625.3m
Thomas Daniel	Scientific Advisor	4.9yrs	US$23.92k	no data
Robert Perez	Independent Director	6.9yrs	US$451.10k	0.012% MX$ 2.6m
Sona Ramasastry	Independent Director	4.3yrs	US$459.94k	0.0079% MX$ 1.8m

6.9yrs

Average Tenure

63yo

Average Age

Experienced Board: VIR *'s board of directors are considered experienced (6.9 years average tenure).

Vir Biotechnology Management

Management criteria checks 1/4

Key information

Recent management updates

Vir Biotechnology, Inc. Announces Executive Appointments

Vir Biotechnology, Inc. Appoints Mark D. Eisner as Executive Vice President and Chief Medical Officer, Effective June 3, 2024

Vir Biotechnology, Inc., Annual General Meeting, May 29, 2024

Vir Biotechnology, Inc., Annual General Meeting, May 29, 2024

Vir Biotechnology, Inc. Announces Phil Pang Will Step Down as Chief Medical Officer

Vir Biotechnology, Inc. Appoints Jennifer Towne, Ph.D., as Executive Vice President and Chief Scientific Officer

Recent updates

Vir Biotechnology, Inc. Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program

Vir Biotechnology, Inc. Announces Positive End-Of-T Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the March Study at AASLD The Liver Meeting

Vir Biotechnology, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Vir Biotechnology, Inc. Announces Executive Appointments

Vir Biotechnology, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Vir Biotechnology, Inc.(NasdaqGS:VIR) dropped from Russell 2000 Value-Defensive Index

Vir Biotechnology, Inc. Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection

Vir Biotechnology, Inc. Announces New Preliminary Data from its Phase 2 SOLSTICE Hepatitis Delta Clinical Trial Evaluating tobevibart, an Investigational Monoclonalantibody, and Elebsiran

Vir Biotechnology, Inc. Appoints Mark D. Eisner as Executive Vice President and Chief Medical Officer, Effective June 3, 2024

Vir Biotechnology, Inc., Annual General Meeting, May 29, 2024

Vir Biotechnology, Inc., Annual General Meeting, May 29, 2024

Vir Biotechnology, Inc. to Report Q1, 2024 Results on May 02, 2024

Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule

Vir Biotechnology, Inc. Announces Phil Pang Will Step Down as Chief Medical Officer

Vir Biotechnology, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Vir Biotechnology, Inc. Appoints Jennifer Towne, Ph.D., as Executive Vice President and Chief Scientific Officer

Vir Biotechnology, Inc. Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD’s the Liver Meeting® 2023

Vir Biotechnology, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Vir Biotechnology, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Biomedical Advanced Research and Development Authority Awards Funding to Vir Biotechnology, Inc. to Support Development of Antibody Platform Technologies for Global Infectious Disease Threats

Vir Biotechnology, Inc. Announces That Johanna Friedl-Naderer, the Company’s Executive Vice President and Chief Operating Officer, Will Be Leaving the Company on September 29, 2023

Vir Biotechnology, Inc. Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age